A5061555101- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cardiac tumors and thrombi
- Vascular Tumors and Angiosarcomas
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Hematological disorders and diagnostics
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Blood disorders and treatments
- Neurofibromatosis and Schwannoma Cases
- Diagnosis and treatment of tuberculosis
- Phytochemistry and biological activity of medicinal plants
- Medicinal Plants and Bioactive Compounds
- Phytochemistry and Biological Activities
- Immunodeficiency and Autoimmune Disorders
University of Arizona
2021-2025
University of Arizona Cancer Center
2021-2024
Banner - University Medical Center Tucson
2024
University Hospitals of Cleveland
2024
Banner Health
2024
Sylvester Comprehensive Cancer Center
2018-2021
University of Miami
2018-2021
Oncology Institute of Hope and Innovation
2021
Jackson Memorial Hospital
2018-2020
St Mary's Hospital
2016
To develop recommendations for systemic therapy well-differentiated grade 1 (G1) to 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
We performed a retrospective analysis of angiosarcoma (AS) genomic biomarkers and their associations with the site origin in cohort 143 cases. Primary sites were head neck (31%), breast (22%), extremity (11%), viscera (20%), skin at other locations (8%), unknown (9%). All cases had Next Generation Sequencing (NGS) data 592 gene panel, 53 Whole Exome (WES) data, which we used to study microenvironment phenotype. The immunotherapy (IO) response Tumor Mutation Burden (TMB), Microsatellite...
537 Background: A+B is the preferred first-line (1L) standard of care for uHCC, with emerging RW evidence supporting its use in a broad patient (pt) cohort. We evaluated pt characteristics, clinical and treatment outcomes pts treated at five U.S. institutions: Mayo Clinic, Houston Methodist, Moffitt Cancer Center, Mays University Arizona. Methods: This retrospective study uHCC who initiated after January 1, 2019. De-identified data were extracted by treating oncologists. Overall survival...
GI stromal tumor (GIST) is the most common sarcoma of tract. Management patients with GIST determined by KIT, PDGFRA, or other genomic alterations. Tissue-based next-generation sequencing (NGS) analysis standard approach for diagnosis, prognosis, and treatment selection. However, circulating DNA (ctDNA)-based NGS a novel noninvasive alternative.ctDNA results were evaluated in blood samples from 243 de-identified within Guardant360 database. Under an approved institutional review board...
Gastrointestinal cancers represent one of the more challenging to treat. Current strategies cure and control gastrointestinal (GI) like surgery, radiation, chemotherapy, immunotherapy have met with limited success, research has turned towards further characterizing tumor microenvironment develop novel therapeutics. Myeloid-derived suppressor cells (MDSCs) emerged as crucial drivers pathogenesis progression within in GI malignancies. Many MDSCs clinical targets been defined preclinical...
In Brazil, cancer is the second most common cause of death. Most patients in resource-limited countries are diagnosed advanced stages. Current guidelines advocate for EGFR mutation testing all with metastatic adenocarcinoma. Tyrosine kinase inhibitors recommended or disease harboring sensitizing mutations. there limited data regarding frequency and changes patterns overtime.This was an observational, retrospective study. We obtained deidentified from a commercial database, which included...
Leiomyosarcoma is a malignant mesenchymal tumor of cells smooth muscle lineage arising commonly in retroperitoneum, uterus, large veins, and the limbs. The genetics leiomyosarcomas are complex there very limited understanding common driver mutations. Circulating DNA (ctDNA) offers rapid noninvasive method next-generation sequencing (NGS) that could be used for diagnosis, therapy, detection recurrence.ctDNA testing was performed using Guardant360, which detects single nucleotide variants,...
We performed a comprehensive analysis of angiosarcoma (AS) genomic biomarkers and their associations with the site origin. aimed to describe landscape AS in cohort 143 cases profiled by Caris Life Sciences. Data Next Generation Sequencing (NGS) 592 gene panel was available for entire cohort. Fifty-three had data Whole Exome (WES) which we used study microenvironment phenotype. Immuno-therapy (IO) response biomarkers: Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) PD-L1 status...
e16104 Background: Gastric adenocarcinoma (GAC) is the fifth most common cancer worldwide with significant morbidity and mortality. Recently, southern Arizona has seen a concerning surge in incidence of GAC due to ineffective H. pylori screening treatment. Moreover, peri-operative chemotherapy treatment stage IB-III represents an area unmet need for new targets. Our center serves catchment that 40% Hispanic sees high volume patients, making this our research focus. preclinical work...
Esophageal squamous cell carcinoma (ESCC) constitutes an aggressive subset of esophageal cancers that portends a poor prognosis. Management ESCC has been historically challenging due to the limited effective therapeutic options. Broadening our understanding molecular landscape and identifying reliable biomarkers are essential in early detection, monitoring disease response advancing treatment strategies. Recently, immunotherapy tyrosine kinase inhibitors have changed algorithm ESCC. In this...
Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Tumors evade immune surveillance by expressing PD-L1 that interacts with T cell protein PD-1, subsequently inhibiting CD8+ cytotoxic lymphocyte proliferation and effector function. A plausible reason for this observation may be other, redundant, suppressive mechanisms are at play. Our research team has shown elevated infiltration polymorphonuclear (PMN)-MDSCs within PDAC tumor...
Cases of concurrent duodenal adenocarcinoma and gastrointestinal stromal tumors (GISTs) are rare, only a few have been reported. While some cases other synchronous primary with GIST reported, no shared mutations consistently found, creating challenges in selecting chemotherapy inoperable tumors. Here, we presented case stage IIIA locally advanced/unresectable metastatic small bowel successfully being treated combined imatinib modified folinic acid, 5-fluorouracil, irinotecan (mFOLFIRI) regimen.
11514 Background: Tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for advanced GIST via pharmacologic targeting of driver oncogenes such as KIT. Detection KIT alterations through tissue-based next-generation sequencing (NGS) is common, but circulating tumor DNA (ctDNA)-based NGS a less invasive alternative to identify and resistance mutations in GIST. Patients (pts) with KIT-mutant benefit from first-line (1L) imatinib; however, may confer imatinib-resistance differential...
11539 Background: GIST is the most common sarcoma of GI tract. Management determined by KIT, PDGFR, or other genomic alterations. Tissue diagnosis has been mainstay biomarker assessment but next generation sequencing (NGS) - based analysis ctDNA a novel, effective and non-invasive alternative. Methods: DNA circulating tumor (ctDNA) was perfomed on blood samples from 152 patients. Samples were collected, shipped at room temperature centrifuged to isolate plasma. extracted, concentrated,...
11044 Background: Leiomyosarcoma is a malignant mesenchymal tumor of cells smooth muscle lineage arising commonly in retroperitoneum, uterus, large veins, and the limbs. In contrast to many sarcomas, genetics leiomyosarcomas are complex there very limited understanding common driver mutations. Circulating Tumor DNA (ctDNA) offers rapid non-invasive method next-generation sequencing (NGS) that could be utilized for diagnosis, therapy detection recurrence. Methods: ctDNA testing was performed...
11545 Background: Targeted therapies for angiosarcoma (AS) patients have limited efficacy. Although significant responses to immunotherapy (IO-therapy) been observed in cutaneous AS, its efficacy across all types of AS is not known. Herein, we describe genetic and molecular biomarkers order propose potential therapeutic options. Methods: We retrospectively reviewed 143 tumors profiled by Next-Generation Sequencing (NGS) 592-gene panel (Caris Life Sciences,Irving, TX, USA). Whole...
Aim: To explore data on non alcoholic fatty liver disease. For this systematic review, our major purpose is to compare grading of disease diagnosed ultrasound with cholesterol level and enzymes. Methodology: study, total 25 studies were included which follow the Preferred Reporting Items guideline for conducting review analysis (PRISMA). We search electronic articles from year 2008 2020 PUB Med, online Willey library, ScienceDirect site by using keywords related sonographic imaging Results:...
2654 Background: Despite receiving identical standard-of-care therapies, epidemiological data indicate that Native American (NA) patients (pts) with cancer have worse outcomes vs. White pts. ICIs revolutionized the treatment of certain tumors, however pts from racial and ethnic groups, including NA pts, are underrepresented in ICI trials. Methods: This is an ongoing multi-center retrospective study across four U.S. academic centers serve a high volume We included self-reported race as...